Pierre Johansen - Publications, H-index & Citations

Pierre Johansen

b novo nordisk denmark a/s, copenhagen, denmarkhttps://orcid.org/0000-0002-6287-7508

16H指数

77论文数

714被引数

收录论文 33

发表时间

Impact of systemic inflammation on healthcare resource utilization and cost in patients with atherosclerotic cardiovascular disease and chronic kidney disease 系统性炎症对动脉粥样硬化性心血管疾病和慢性肾脏病患者医疗资源利用及成本的影响

Journal of Medical Economics

IF3

2025-08-12

OAAI

Jan Håkon Rudolfsen; Jelena Vukmirica; Pierre Johansen; Kasper Løwe Røder; Martin Bødtker Mortensen

The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes

JHEP REPORTS

IF7.5

2022-09-01

OAAI

Younossi, Zobair; Aggarwal, Priya; Shrestha, Ichhya; Fernandes, Joao; Johansen, Pierre; Augusto, Margarida; Nair, Sunita

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2020-08-22

OAAI

Lingvay, Ildiko; Capehorn, Matthew S.; Catarig, Andrei-Mircea; Johansen, Pierre; Lawson, Jack; Sandberg, Anna; Shaw, Robert; Paine, Abby

Once-Weekly Semaglutide 1mg vs. Empagliflozin 25mg as Add-On to Metformin Monotherapy in Patients with Type 2 Diabetes: A Meta-regression Analysis of Individual Patient Data

DIABETES

IF7.5

2020-06-01

PREAI

Lingvay, Ildiko; Catarig, Andrei-Mircea; Sandberg, Anna; Lawson, Jack; Capehorn, Matthew; Johansen, Pierre; Shaw, Robert D.; Paine, Abby

Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden

DIABETES OBESITY & METABOLISM

IF5.7

2020-05-22

OAAI

Persson, Sofie; Johansen, Pierre; Andersson, Emelie; Lindgren, Peter; Thielke, Desiree; Thorsted, Brian L.; Jendle, Johan; Carlsson, Katarina Steen

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK

ADVANCES IN THERAPY

IF4

2020-04-18

OAAI

Johansen, Pierre; Chubb, Barrie; Hunt, Barnaby; Malkin, Samuel J. P.; Sandberg, Anna; Capehorn, Matthew

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK

ADVANCES IN THERAPY

IF4

2020-02-11

OAAI

Johansen, Pierre; Sandberg, Anna; Capehorn, Matthew

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA (vol 36, pg 1190, 2019)

ADVANCES IN THERAPY

IF4

2019-04-12

OAAI

Johansen, Pierre; Hunt, Barnaby; Iyer, Neeraj N.; Tam Dang-Tan; Pollock, Richard F.

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA

ADVANCES IN THERAPY

IF4

2019-03-14

OAAI

Johansen, Pierre; Hunt, Barnaby; Iyer, Neeraj N.; Tam Dang-Tan; Pollock, Richard F.

Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK

DIABETES OBESITY & METABOLISM

IF5.7

2018-11-28

OAAI

Viljoen, Adie; Hoxer, Christina S.; Johansen, Pierre; Malkin, Samuel; Hunt, Barnaby; Bain, Stephen C.

Cost-Effectiveness of Once-Weekly Semaglutide 1.0 mg vs. Dulaglutide 1.5 mg as Add-On to Metformin in the Treatment of Type 2 Diabetes in Canada

DIABETES

IF7.5

2018-07-01

PREAI

Johansen, Pierre; Hakan-Bloch, Jonas; Liu, Aiden R.; Persson, Sofie; Grip, Emilie Toresson

Incorporating Cardioprotective Effects of Once-Weekly Semaglutide in Estimates of Health Benefits for Patients with Type 2 Diabetes

DIABETES

IF7.5

2018-07-01

PREAI

Evans, Marc; Johansen, Pierre; Vrazic, Hrvoje

EVALUATION OF THE COST PER PATIENT ACHIEVING COMPOSITE AND SINGLE TREATMENT TARGETS WITH ONCE-WEEKLY SEMAGLUTIDE AND EXENATIDE ER IN THE UNITED STATES

VALUE IN HEALTH

IF6

2018-05-01

OAAI

Pollock, R. F.; Johansen, P.; Hunt, B.; Iyer, N. N.; Dang-Tan, T.; Wilkinson, L.

UPDATE OF THE MODEL VALIDATION OF THE ECONOMIC AND HEALTH OUTCOMES MODEL OF TYPE 2 DIABETES MELLITUS (ECHO-T2DM)

VALUE IN HEALTH

IF6

2016-05-01

OAAI

Asseburg, C.; Willis, M.; Johansen, P.; Nilsson, A.; Neslusan, C.; Schroeder, M.

TIME UNTIL INSULIN INITIATION FOR CANAGLIFLOZIN VERSUS DAPAGLIFLOZIN AND EMPAGLIFLOZIN IN DUAL AND TRIPLE THERAPY FOR TYPE 2 DIABETES MELLITUS IN THE UNITED KINGDOM

VALUE IN HEALTH

IF6

2016-05-01

OAAI

Schroeder, M.; Chan, E.; Willis, M.; Johansen, P.; Nilsson, A.; Schubert, A.; Neslusan, C.

COST OF ACHIEVING COMBINED IMPROVEMENTS IN HBA1C AND WEIGHT WITHOUT HYPOGLYCAEMIA OVER 4 YEARS IN A POST-HOC ANALYSIS OF DAPAGLIFLOZIN plus MET VS GLIPIZIDE plus MET

VALUE IN HEALTH

IF6

2015-11-01

OAAI

Johansen, P.; Mukherjee, J.; Sorstadius, E.; Sternhufvud, C.

THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) 10MG AND EMPAGLIFLOZIN (EMPA) 25MG IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS MONOTHERAPY IN THE UNITED KINGDOM

VALUE IN HEALTH

IF6

2015-11-01

OAAI

Schroeder, M.; Johansen, P.; Willis, M.; Neslusan, C.

COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL

VALUE IN HEALTH

IF6

2015-11-01

OAAI

Pititto, L.; Neslusan, C.; Teschemaker, A. R.; Johansen, P.; Willis, M.; Asano, E.; Puig, A.

THE EFFECT OF TREATMENT INTENSIFICATION ASSUMPTIONS ON ESTIMATES OF COST-EFFECTIVENESS IN TYPE 2 DIABETES MELLITUS (T2DM)

VALUE IN HEALTH

IF6

2015-05-01

OAAI

Willis, M.; Johansen, P.; Neslusan, C.

TIME UNTIL INSULIN INITIATION FOR CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN DUAL AND TRIPLE THERAPY FOR TYPE 2 DIABETES MELLITUS (T2DM) IN IRELAND

VALUE IN HEALTH

IF6

2015-05-01

OAAI

Bacon, T.; Willis, M.; Johansen, P.; Neslusan, C.

研究方向